SOURCE: Xtalks

Xtalks Webinars

April 02, 2015 07:05 ET

Inhalation Exposure Systems for Aerosol Delivery Advancements: Perspective From a Bench Scientist, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - April 02, 2015) - Join esteemed speakers Aileen House, Sr. Scientist, In Vivo Pharmacology -- Cardiovascular Department at Merck & Co Pharmaceuticals, and Michael Girand, Principal Applications Engineer at Data Sciences International (DSI), for an information session. The live broadcast takes place on Thursday, April 30, 2015 at 11am EDT / 4pm BST (UK GMT +1).

Inhalation exposure systems for preclinical research have evolved since their introduction in the early 1900s to meet the needs of many different research applications. These systems vary significantly depending on the type of research being conducted, which can include: Inhalation Toxicology, Biodefense Aerobiology, Pharmaceutical, Discovery and Drug Development, Basic Respiratory Physiology, and Environmental Toxicology and Exposure studies. With each of these research disciplines, the scientific approach will differ, as will the complexity of the study design and the desired endpoints. As a result, the type of equipment required will also differ. With each inhalation delivery method and application, a host of benefits and potential disadvantages follow.

Delivering aerosol compounds for preclinical inhalation research has been historically challenging. Even today, many inhalation exposure systems require large amounts of API (active pharmaceutical ingredient) and invasive techniques that necessitate anesthesia and intratracheal administration. Such techniques have potential disadvantages because they are not representative of methods used in clinical settings. The use of mass dosing chambers for delivery of an inhaled substance eliminates the issue of anesthesia and allows the animal to be unrestrained and roam freely. However, this approach may result in excess use of API and be an inefficient method to deliver compound to the animal's lungs.

Scientists from Merck & Co. pharmaceuticals determined that there was a need to develop a superior system for the delivery of liquid and dry powder aerosols. With input from Merck, Buxco Research Systems (which was acquired by Data Sciences International [DSI] in 2014) developed and validated a 14-port inhalation tower. The tower, with its all-in-one controller, patented AllayTM restraint collar for rodents, and nose-only plethysmograph to deliver small amounts of API continuously to conscious rats, gives the researcher peace of mind that an inhaled substance will be delivered to all animals in a uniform and reproducible manner.

This webinar will include a discussion about inhalation exposure systems, specifically:

  • The variety of inhalation exposure applications currently being used in research, along with their advantages and disadvantages
  • Identifying the need for better inhalation exposure tools
  • Introduction of DSI's 14-Port Inhalation Tower and All-in-One Tower Controller
  • Scientific perspective of 14-Port Inhalation Tower

For more information about this event visit: Inhalation Exposure Systems for Aerosol Delivery Advancements: Perspective from a Bench Scientist

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2015/3/31/11G037201/Images/DSI_logo300-426975556825.jpg

Contact Information